Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
Clinical trial NCT03871153 · TERMINATED
Trial details
- NCT number
- NCT03871153
- Sponsor
- Greg Durm, MD
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-02
- Primary completion
- 2021-10-30
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.